Comparative In Vitro Activities of SMT19969, a New Antimicrobial Agent, Against 162 Strains from 35 Less Frequently Recovered Intestinal Clostridium Species: Implications for Clostridium difficile Recurrence
You are leaving Smmttx.com
You have selected a link that will take you to a site maintained by a third party who is solely responsible
for
its contents.
Summit Therapeutics, Inc., is not responsible for the privacy notice of any third-party websites. We encourage you to read the privacy notice of every website you visit.
To stay on Summit’s website, click “Cancel” or click “Continue” to proceed.
Comparative In Vitro Activities of SMT19969, a New Antimicrobial Agent, Against 162 Strains from 35 Less Frequently Recovered Intestinal Clostridium Species: Implications for Clostridium difficile Recurrence